Alzamend Neuro (ALZN)
Develops AL001 and ALZN002 candidates for Alzheimer’s disease and psychiatric disorders.
Something off on this page? Send us feedback.
Develops AL001, a lithium-delivery candidate for Alzheimer’s disease and psychiatric indications, and ALZN002, a patient-specific immunotherapy for Alzheimer’s disease. With no approved products or revenue, progress depends on clinical development, regulatory review, licensing and third-party execution.
Develops two licensed, clinical-stage candidates. AL001 is an ionic cocrystal intended to change lithium delivery for Alzheimer’s disease, bipolar disorder, major depressive disorder and PTSD; ALZN002 is a patient-specific dendritic-cell immunotherapy designed to encourage anti-amyloid immune activity in Alzheimer’s disease.
Operates through an asset-light, U.S.-centered model: core technology is licensed from the University of South Florida Research Foundation, while consultants, contract research organizations and third-party manufacturers support development and supply. AL001 imaging studies compare its delivery profile with lithium carbonate; ALZN002’s trial remains delayed after its CRO ended the engagement.
Has no approved products, product revenue or manufacturing facilities. Commercialization depends on clinical results, regulatory approval, continued license rights and outsourced clinical, manufacturing and trial-execution capacity.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jul 31, 2026Cash & short-term investments $7.6M · Total debt $0 · Total assets $8.5M · Shareholders' equity $5.8M
- Revenue
- $0
- Operating income
- −$3.0M
- Net income
- −$3.0M
No dividends on record.
| Institutions | 17.93% | 682.2K shares | |
|---|---|---|---|
| 13 holders · as of Mar 31, 2026 | |||
| Insiders | 3.14% | 119.3K shares | |
| 3 holders · as of Aug 31, 2026 | |||
| Other | 78.93% | 3.00M shares | |
| remainder | |||
3.80M company shares as of Aug 22, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (4.83M in the company's Sep 23, 2026 report, 3.80M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Kingsbury Capital Investment Advisors LLCInstitution | 14.90% | 566,733 | as of Mar 31, 2026 |
Milton C. Iii Ault1Insiderdirector | 3.12% | 118,648 | filed Aug 31, 2026 |
Geode Capital Management, LLCInstitution | 1.20% | 45,680 | as of Mar 31, 2026 |
Vanguard Fiduciary Trust CoInstitution | 0.55% | 21,020 | as of Mar 31, 2026 |
Morgan StanleyInstitution | 0.47% | 18,000 | as of Mar 31, 2026 |
- Reported at 4.40% on Oct 7, 2025, under the 5% line, so no further filing is required.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Apr 14, 2026 | Milton C. Iii Ault | director | +110,388 | $1.01 |
| Aug 26, 2026 | Milton C. Iii Ault | director | −2,000 | $1.56 |
| Dec 23, 2025 | Milton C. Iii Ault | director | −1,851 | $2.07 |
| Dec 19, 2025 | William B. Horne | director | −3,333 | $2.12 |
| Oct 23, 2025 | Lynne Fahey McGrath | director | −30 | $2.29 |
- Eli Lilly
Kisunla leads a large-scale anti-amyloid Alzheimer's challenge.
- Axsome Therapeutics
Auvelity overlaps in MDD and Alzheimer's-dementia symptoms.
- Johnson & Johnson
CAPLYTA and SPRAVATO span bipolar depression and MDD.
- Biogen
Leqembi commercialization brings a scaled anti-amyloid rival.
- AbbVie
VRAYLAR overlaps in bipolar depression and adjunctive MDD.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Alzamend Neuro | $1.94 | −0.20% | $7.4M | — | — | — | — |
| Eli Lilly | $1,154.58 | −1.33% | $1.10T | 39.3 | 28.2 | 13.8 | +47.7% |
| Axsome Therapeutics | $194.83 | −4.07% | $10.45B | — | 1,162.4 | 13.5 | +44.2% |
| Johnson & Johnson | $268.58 | −0.23% | $648.72B | 31.2 | 22.6 | 6.6 | +6.6% |
| Biogen | $223.97 | −0.62% | $33.30B | 39.9 | 16.9 | 3.3 | +3.4% |
| AbbVie | $264.74 | −0.18% | $468.77B | 74.8 | 17.4 | 7.3 | +10.2% |
| Median | 39.6 | 22.6 | 7.3 | +10.2% |